Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2024-04-23), Sinopharm Group Co's Intrinsic Value: Projected FCF is $8.18. The stock price of Sinopharm Group Co is $2.61. Therefore, Sinopharm Group Co's Price-to-Intrinsic-Value-Projected-FCF of today is 0.3.
The historical rank and industry rank for Sinopharm Group Co's Intrinsic Value: Projected FCF or its related term are showing as below:
SHTDF'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 0.27 Med: 0.86 Max: 1.41
Current: 0.32
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Sinopharm Group Co was 1.41. The lowest was 0.27. And the median was 0.86.
SHTDF's Price-to-Projected-FCF is ranked better than 95.31% of 64
companies
in the Medical Distribution industry
Industry Median: 1.025
vs SHTDF: 0.32
Sinopharm Group Co Intrinsic Value: Projected FCF Historical Data
The historical data trend for Sinopharm Group Co's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Sinopharm Group Co's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Group Co Price-to-Projected-FCF Distribution
For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Sinopharm Group Co's Price-to-Projected-FCF falls into.
Sinopharm Group Co Intrinsic Value: Projected FCF Calculation
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinopharm Group Co (OTCPK:SHTDF) Intrinsic Value: Projected FCF Explanation
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Sinopharm Group Co's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
2.61
/
7.1216098351437
=
0.37
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinopharm Group Co Intrinsic Value: Projected FCF Related Terms
Thank you for viewing the detailed overview of Sinopharm Group Co's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Sinopharm Group Co (Sinopharm Group Co) Business Description
Sinopharm Group was founded in 2003 and listed on the Hong Kong Stock Exchange in September 2009. Its main business is drug distribution in mainland China, which contributes about 75% of total revenue. It is the largest drug distributor, with approximately 20% market share. Other notable segments are medical device distribution, which contributes about 20% of revenue, and retail pharmacies, which contributes about 5%. These are fast-growing industries, where government policy is designed to encourage consolidation and promote large players with scale and efficiency advantages.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SHTDF has been successfully added to your 